Serum glucocorticoid levels were determined in 20 mothers and 43 premature infants who received prenatal betamethasone therapy for prevention of respiratory distress syndrome (RDS). Maternal betamethasone peaked at 75 microg cortisol equivalents per 100 ml 1 h after injection of 12 mg steroid and declined to half by 6 h. Betamethasone in cord blood was 14.3 microg cortisol equivalents per 100 ml at 1 h, decreased to a level of 4.7 at 20 h, and was not detected 2 days after a second dose at 24 h. After the second dose, the mean level of cortisol in cord blood was 5.9 microg per 100 ml compared with 13.05 microg per 100 ml (p less than 0.001) in untreated premature infants. The unbound glucocorticoid activity in treated infants delivered 1-10 h after the second dose (mean, 8.4 microg per 100 ml) is similar to the unbound cortisol level after birth in untreated premature infants who develop RDS. These findings indicate that (a) serum glucocorticoid levels in the physiologic stress range can induce lung maturation in the human and (b) antenatal treatment with this dose of betamethasone does not expose the human fetus to potentially harmful pharmacologic levels of steroid. to half by 6 h. Betamethasone in cord blood w-as 14.3 tig cortisol equivalents per 100 ml at 1 h, decreased to a level of 4.7 at 20 h, aand was not detected 2 days after a second dose at 24 h. After the second dose, the mean level of cortisol in cord blood was 5.9 yg per 100 ml compared witlh 13.05 y-per 100 ml (P < 0.001) in untreated premature infanits. The unbound glucocorticoid activity in treated infants delivered 1-10 h after the second dose (mean, 8.4 Ag per 100 nil) is simlilar to the unbound cortisol level after birth in untreated premature infants who develop RDS.
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INTRODUCTION
Admiiinistration of glucocorticoids to fetal animilals of several species accelerates lung development and causes precocious appearance of alveolar surfactaint (3) (4) (5) .
Portions of this work were submitted for the meetings of the Western Society for Pediatric Researclh, Carmel, Calif., February 1975 (1) , and the Society for Pediatric Researclh, Denver, Colo., April 1975 (2) .
Rccived for puZblicationi 10 Juniie 19/75 anid in rvi.sed form 20 Autgust 1915.
Since a deficiency of surfactant is the major causse of resl)iratory distress svnldrome ( S) ' illpremlltlue human illfatn,ts, these tifi(lilln s SUg'gested that -lticocorticoids imliglht benefit the human infanit at risk for this (lisease. Recently, Liggins and Hox-ie (6, 7) reported a significantly lower incideince of RDS in preimlature ii fanits wh-lose mothers were treated w-itlh betamiiethasonie for at least 24 h before deliverv. In a simiillar studv, Fargier et al. (8) also noted a beneficial effect of prenatal betamiietlhasoine therapy. These stuclies have indicated the effectiveness of prenatal glucocorticoidl treatment for prevention of RDS, aild it seellms likely that suclh therapy ws1ill comiie into general use in the future.
At present, however, little is knownNIl regai-dinlg the level of glucocorticoidl require(l to ilndtuce lun-g imiaturationl in lhlumanc infantcs. Also, tlher-e is little iinformiiationl conicerninig the safety of prenat,al corticosteroid administration. It does appear that the lunlg is a glucocorticoid target tissue sinice both animal (9, 10) and lhumiani ('11) fetal luIg contain specific receptors for glucocorticoids. These bindin-proteins are saturated by physiolog,ic levels of corticosteroidls, suggesting that the (lesire(d nmaturational effects slhould he accomplished without the use of pharmacologic doses of steroid. This is anlnil)ortant conlsi(leratioln silnce it is knlowII that large (loses of corticosteroids inhibit growvth in many organs of fetal ancd neoinatal aninlds (12) (13) (14) (15) (16) (17) (18) .
In the presenlt studlv, we have (letermiiniedl serumii levels of glucocorticoid activity in the hulmialn mother and fetus at various timles after prelnatal treatmiielnt itlh betamethasonie to prevent RDS. The In order to determine the amount of glucocorticoid activity that was due to betamethasone, serum corticoids were also assayed in the ethanol extracts of each sample by the corticosteroid-binding globulin (CBG)-isotope method of Murphy (20) and the charcoal absorption technique (19) .
This assay does not detect betamethasone. Appropriate control sera (vithout synthetic corticosteroids) were included in each experiment to establish the correlation between results in the two assays. The level of betamethasone was then determined by the amount of excess activity found by radioreceptor assay as compared with the CBG-isotope assay. Serum concentrations are expressed as cortisol equivalents and reflect the relative affinity of betamethasone for glucocorticoid receptors. Values may be converted to micrograms betamethasone per 100 ml by dividing by 7.1 (19) . The assay under these conditions is sensitive to a level of 2 ,ug cortisol equivalents per 100 ml.
The percentage of serum cortisol bound to transcortin was determined in undiluted sera by a modification of the 2We thank G. C. Liggins and R. N. Howie for providing these samples. (21) with a tracer amount of [3H]cortisol and absorption by activated charcoal as previously described (19) . This method measures binding to transcortin (but not to albumin) and provides results similar to those found by ultrafiltration and equilibrium dialysis at 37 C.3 Transcortin binding was assessed in pooled cord serum samples from premature infants after addition of various amounts of unlabeled cortisol. Transcortin capacity in these and other samples was calculated from the amount of binding at a cortisol level of 50 ,Ag per 100 ml (21) . The amount of unbound cortisol and cortisol bound to albumin was estimated (22) from these data by using published values for cord blood albumin levels in premature infants with and without RDS (23) .
RESULTS
Matcrnal steroid levels. Determiiinations of betamethasone and cortisol levels were carried out on 37 samples of blood from 20 women 0-12 h after the first dose of steroid. Four additional samples were obtained 45-52 h after a second dose (Fig. 1) . The level of betamethasone is maximal (755 j.g cortisol equivalents per 100 ml) at 1 h and then declines to half of this value at about 6 h; little activity remained in the maternal circulation 2 days after the second injection. Cortisol levels begin to decrease within 2 h of the administration of exogenous corticosteroid and reach a level of 5 ug per 100 mg ml at 12 h. During the 2nd day of treatment, cortisol was below 5 Ag per 100 ml in four of five patients (data not shown). 2 days after the second injection, the mean level of cortisol in five women at delivery was within the normal range.
Betamiiethasone levels in cord blood. Steroid levels were measured in samples of cord blood from 43 premature infants exposed to betamethasone in utero. Cord bloods from another group of 22 infants who were delivered at comparable times after treatment with a placebo (6) served as con assay and for comparison of in both groups were deliverc ous labor except for one tr livered by cesarean section. and birth weight, sex dist prolonged rupture of membre in the two groups (Table I) .
Individual cord blood beta on a time scale in Fig. 2 cortin was found to be 49, 53, 59, and 64%, respectively. The ratio of albumin-bound and unbound cortisol within this fraction has been shown previously to depend only on the albumin concentration (22) . Betamethasone is not bound to transcortin (19, 25) , and from the studies of Peets et al. (25) we estimate that 47% is unbound in cord blood of the premature infant. Using these binding data, we have compared the levels of total, albumin-bound, and unbound glucocorticoid activity in betamethasone-treated infants with the levels in normal and stressed premature infants (Table III) . In our study, the mean cortisol level in cord blood of 14 untreated premature infants born without PROM or other maternal or fetal complications was 10.5 Ag per 100 ml, resulting in 2.8 Ag albumin-bound and 2.8 Ag unbound cortisol per 100 ml. In other studies, mean total cortisol levels of about 16 and 22 ,ug per 100 ml have been reported for infants who are born after PROM or who develop RDS shortly after birth, respectively (26) (27) (28) . We also have found similarly elevated cortisol values in a limited number of infants under both conditions (data not presented). The un- bound cortisol levels in these two situations are 4.6 and 7.8 ug per 100 ml, which are in the order of 14 and 3 times that of normal premature infants. In treated infants, both cortisol and betamethasone contribute to the plasma glucocorticoid activity. We calculate that these infants have peak unbound and albumin-bound glucocorticoid levels of 9.4 and 8.4 ug cortisol equivalents per 100 ml, respectively. Betamethasone treatment at this dose, therefore, results in an unbound glucocorticoid level similar to that achieved by endogenous cortisol production in the premature infant with RDS.
DISCUSSION
We have determined serum levels of betamethasone, using a radioreceptor assay for glucocorticoids. This 12 mg at 0 and 18 h). It slhould also be noted that the plasmiia glucocorticoid activity in treated infants falls below control levels during the 3rd day. It is possible that a longer exposure to elevated steroid levels (e.g., a tlhird dose 24 h after the second) would increase the effectiveneis of therapy.
As reported previously (6) , therapy with this dose of synthetic corticosteroid rapidly suppresses maternal cortisol levels. Cortisol in cord blood is also decreased soon after treatment; values were lower after the second injection at a time when betamethasone levels were lighest and maternal cortisol quite loxv. These lower valuies in cord bloo10 probably reflect decrease(l coItisol p)roduction in the fetus as well as in the mlothler. HowNever, in five treated infants with RDS, we found elevated cortisol levels after birth, suggesting that the norimial pituitary-adrenal response to stress is not lost wvith treatment.
Another concern regarding the use of prenatal corticosteroids in human infants is the possibility of adverse effects on grow-tlh. Administrationi of these steroids to fetal and neonatal animals cain seriously iml)air Olrgalnl anid somiatic growth and neurologic functioni (12) (13) (14) (15) (16) (17) (18) . Only somiie of these effects are 1)artially or fully reversed by comlpenisatory catclh-up growstlh after witlhdrawal of steroid (12, 13, 16, 17, 30) . However, the doses of lhormlone per kilogram body w-eiglht used in the animal studies are 15-300 times that which the human fetus receives xvith prenatal betamethlasonie therapy. This is a critical consideration since the extent of the effects in animals is dose related (12, 13, 18 (6, 32) .
In addition, w-e find only a tlhreefold mlaximiial increase in the unbounild glucocorticoid level in premlature infanits exposed to prenatal betamethasone therapy. This level can be compared to the 1ly-and 3-fold increases found in premature infants wlho are delivered after PRO.M or who develop RDS after birth, respectively. Thus, such treatnment exposes the infant to corticoid doses no higher, and for nIo longer, than those wlhich occur by endogenous production in the infant w-itlh RDS. These conmparisons suggest that antenatal betametlhasonie treatment at this dose closely approximates a physiologic stress response. It seems unlikely, thouglh unprovein, that this level of corticoid is hazardous to the premature infant.
Our findings also indicate that prevention of RDS occurs with serum glucocorticoid levels in the physiologic stress range, suggesting that such levels are sufficient to induce lung maturation in the human fetus. This is consistent with a direct glucocorticoid effect in lung mediated by the receptor system since the levels 1552 P. L. Ballard, P. Granberg, and R. A. Ballard of serum glucocorticoid activity after treatment would be sufficient to fill all receptor sites and thereby evoke an optimal response. The elevated corticoid levels associated with PROM and RDS suggest that endogenous cortisol may act by the same mechanism to accelerate pulmonary development in these situations. It is also possible that during normal gestation the appearance of alveolar surfactant is triggered by an increase in endogenous cortisol levels. In this regard, Murphy (33) has reported that higher levels of cortisol in cord blood are associated with less RDS, and Fencl and Tulchinsky (34) have noted an increase in amniotic fluid cortisol after 34 wk gestation in normal pregnancies. Thus, the level of endogenous corticosteroid may be an important regulatory factor in both the pathogenesis and prevention of this disease. In this case, administration of prenatal glucocorticoids in appropriate circumstances may accelerate developmental events in the lung through normal physiologic mechanisms.
